Chronic kidney disease (CKD) is primarily a disease of aging. More than 50% of adults over age 70 have an eGFR below 60 mL/min/1.73m² — meeting the laboratory threshold for CKD — and kidney function declines physiologically with age even in the absence of kidney-specific disease. The intersection of CKD and aging creates clinical challenges that are distinct from CKD in younger patients: older adults with CKD are more likely to have multiple concurrent conditions (heart disease, diabetes, hypertension, arthritis, osteoporosis), take many medications with complex interaction risks, experience frailty and sarcopenia that amplify the physical effects of CKD, and face different priorities in weighing the benefits and burdens of aggressive versus conservative CKD management. For older adults and their families, understanding how CKD and aging interact — and how care goals and treatment decisions should be adapted to this context — is essential for making informed choices that align with individual values and functional goals. This article addresses the specific dimensions of CKD in older adults: the physiology of aging kidneys, the importance of distinguishing age-related kidney decline from disease-driven CKD, the management of frailty and sarcopenia, polypharmacy risks, and how treatment goals for dialysis and transplant are appropriately individualized in older patients. For the broader context of CKD complications that affect older adults — including cardiovascular risk, anemia, and bone health — the companion articles on kidney disease and heart health and kidney disease and bone health provide relevant detail.
How Aging Affects the Kidneys: Normal Decline Versus Disease
A critical distinction for older adults and their care teams is understanding how much kidney function decline is an expected part of normal physiological aging versus how much reflects a superimposed disease process that might be preventable, treatable, or at least decelerating. Normal age-related kidney changes: after age 30–40, GFR declines at approximately 0.7–1 mL/min/1.73m² per year as a normal part of aging — without any identifiable disease process. This decline reflects: reduced renal blood flow (from reduced cardiac output and arterial stiffening); nephron loss (the total number of functional nephrons decreases by approximately 30–40% between age 25 and 85 in healthy individuals); reduced glomerular filtration efficiency per remaining nephron; and reduced tubular function (impairing the ability to concentrate urine, excrete acid, and respond to electrolyte challenges). By this natural trajectory, a healthy 80-year-old with no kidney disease may have an eGFR of 50–60 mL/min — meeting the laboratory threshold for CKD stage 3 without having any kidney-specific pathology. Identifying true CKD versus age-related decline: the key indicators that kidney function decline exceeds expected aging include: proteinuria (protein in urine is not a normal aging phenomenon and indicates glomerular damage); a rate of eGFR decline significantly faster than 1 mL/min/year; hematuria (blood in urine) unexplained by urological causes; or eGFR below 30 mL/min in the absence of other disease that typically drives such decline. Older adults whose kidney function appears to be declining faster than expected for age deserve evaluation for superimposed causes — uncontrolled hypertension, diabetes nephropathy, glomerular disease, recurrent UTIs — that may be modifiable. The risks of over-diagnosis in older adults: labeling an 80-year-old with an eGFR of 55 as having “chronic kidney disease” when their kidney function is normal for their age creates unnecessary anxiety, leads to unnecessary dietary restrictions, and may drive over-testing. KDIGO guidelines acknowledge this complexity by noting that in elderly individuals with stable eGFR and no other kidney damage markers (proteinuria, hematuria), some degree of low eGFR may not warrant a CKD diagnosis or aggressive management. The conversation with the care team should focus on the rate of change and the presence of kidney damage markers, not just a single eGFR number. Interpreting eGFR in older adults: standard eGFR formulas (CKD-EPI) use serum creatinine, age, and sex to estimate GFR. In older adults — particularly elderly women and frail patients with reduced muscle mass — creatinine-based eGFR may overestimate true GFR because low muscle mass produces less creatinine, making the serum creatinine appear lower than expected for the actual GFR. Cystatin C-based eGFR estimation is less affected by muscle mass and may provide a more accurate assessment in frail elderly patients. The NIDDK CKD information for older adults is at the NIDDK CKD information page.
Frailty, Sarcopenia, and Physical Function in CKD and Aging
Frailty — a state of decreased physiological reserve and vulnerability to stressors, characterized by weakness, weight loss, exhaustion, low physical activity, and slow gait speed — is substantially more prevalent in CKD patients than in age-matched non-CKD individuals, and its prevalence increases dramatically with advancing CKD stage. Frailty in CKD is not simply “being old” — it is a distinct clinical syndrome with specific causes and consequences in kidney disease, and it can be assessed, managed, and partially reversed. Prevalence of frailty in CKD: frailty affects approximately 20–30% of CKD stage 3–4 patients, 40–50% of dialysis patients, and up to 70–80% of pre-transplant candidates in some series. These rates are 3–5 times higher than in the general elderly population of similar age. Frailty powerfully predicts adverse outcomes in CKD: frail CKD patients have higher rates of hospitalization, falls and fractures, dialysis-related complications, post-transplant complications, and mortality compared to non-frail CKD patients of the same age and eGFR. Mechanisms driving frailty in CKD: multiple CKD-specific mechanisms accelerate the development of frailty. Protein-energy malnutrition — from anorexia (reduced appetite from uremia), dietary protein restriction, and metabolic acidosis-driven protein catabolism — reduces muscle mass (sarcopenia) and physical function. Metabolic acidosis directly stimulates proteasomal and lysosomal muscle protein degradation. Chronic inflammation (from uremia, oxidative stress, and secondary infections in dialysis patients) drives the same inflammatory pathways that produce sarcopenia in cancer cachexia. Anemia contributes to fatigue and reduced exercise capacity. Vitamin D deficiency impairs muscle function directly (in addition to its bone effects). Physical inactivity — driven by fatigue, dialysis scheduling, and fear of overexertion — creates a deconditioning spiral that worsens frailty over time. Assessing frailty in CKD: the Fried Frailty Phenotype (five components: unintentional weight loss, exhaustion, weakness by grip strength, slow walking speed, and low physical activity) is the most validated tool in CKD populations. The Clinical Frailty Scale (a visual analog scale of 1–9 rating functional independence) is quick to administer. Either can be used at nephrology visits to objectively quantify frailty and track change over time. Addressing frailty in CKD: exercise-based interventions are the most evidence-supported approach to frailty in CKD. Resistance training (using light weights or resistance bands) and aerobic exercise both improve muscle strength, physical function, and quality of life in CKD patients, including those on dialysis. Intradialytic exercise (during dialysis sessions) is safe and improves functional capacity even in severely deconditioned patients. Nutritional supplementation — adequate dietary protein (0.8–1.2 g/kg/day in non-dialysis CKD, 1.2–1.5 g/kg/day in dialysis) and treatment of protein-energy malnutrition with oral nutritional supplements or appetite stimulants — can partially reverse sarcopenia. The KDIGO guidelines on physical function and frailty in CKD are at the KDIGO CKD evaluation guidelines page.
Polypharmacy, Medication Safety, and Treatment Goals in Older CKD Patients
Polypharmacy — the concurrent use of multiple medications — is nearly universal in older adults with CKD, and it creates specific risks that require active management. Older CKD patients are prescribed medications for hypertension, diabetes, heart disease, bone disease, anemia, and CKD-MBD simultaneously, often by multiple specialists who may not fully account for each other’s prescriptions. The polypharmacy burden in CKD: the median number of medications prescribed to hemodialysis patients is approximately 10–12 medications — a figure that increases further when over-the-counter supplements and pain medications are included. Each additional medication adds risk of drug-drug interactions, adverse effects (many of which are dose-related and worse in CKD due to reduced drug clearance), and adherence failures from complexity. Medication adherence declines steeply as the number of medications increases, and in CKD patients with cognitive impairment, managing complex regimens reliably becomes increasingly difficult. Medications that require dose adjustment or avoidance in CKD: many medications used in older adults accumulate to dangerous levels in CKD due to reduced renal clearance. Metformin (used for type 2 diabetes) is contraindicated below eGFR 30 and requires dose reduction below eGFR 45. NSAIDs (ibuprofen, naproxen, used for pain and arthritis) reduce kidney perfusion and can precipitate acute kidney injury — they should generally be avoided in CKD stage 3 and above. Gabapentin and pregabalin accumulate dramatically in renal failure, causing sedation, confusion, and fall risk at standard doses. Digoxin (occasionally used in heart failure) has a narrow therapeutic index and accumulates in CKD. Nitrofurantoin (used for UTI prevention) is ineffective and potentially toxic in CKD. H2-blockers (famotidine, ranitidine) accumulate in CKD. A complete medication review — including over-the-counter products — with a pharmacist or nephrologist experienced in kidney disease should be performed at least annually for CKD patients taking multiple medications, and whenever eGFR changes significantly. Dialysis decisions in older adults: the decision of whether and when to start dialysis in older adults is among the most important treatment decisions in nephrology — and one where individual values and functional goals, rather than just laboratory values, should drive the decision. Studies in older adults (age 75+) have found that survival benefit from dialysis versus conservative (non-dialytic) management is modest in frail patients and absent in some subgroups, while time spent on dialysis substantially reduces functional time. A significant proportion of older adults who choose dialysis spend a large fraction of their remaining life attending dialysis sessions without meaningful quality-of-life benefit. Shared decision-making — including explicit discussion of conservative kidney management (managing CKD without dialysis, focusing on symptom control and quality of life) — should be offered to older, frail patients with advanced CKD. Conservative management is a legitimate choice, not a failure of care. The NKF guidance on dialysis decision-making is at the NKF dialysis decision resource. For a comprehensive overview of treatment options, the article on kidney failure treatment options covers all modalities including conservative management. The StatPearls reference on frailty in CKD is at the StatPearls frailty resource. For patients managing kidney disease alongside high blood pressure — one of the most common comorbidities in older adults — the article on kidney disease and high blood pressure covers blood pressure targets and medication safety in advanced CKD.
Sources: NIDDK Chronic Kidney Disease · KDIGO CKD Guidelines · National Kidney Foundation · StatPearls: Frailty in CKD
Advance Care Planning and Goals of Care in Older Adults With CKD
Advance care planning — the process of thinking through, discussing, and documenting one’s values, goals, and preferences for future medical care — is particularly important for older adults with CKD, who face a substantial likelihood of reaching decisions about dialysis initiation, dialysis withdrawal, or end-of-life care over the course of their illness. Yet these conversations are consistently inadequate in nephrology practice: surveys consistently find that most CKD patients have not discussed their goals of care with their nephrologist, and many do not have advance directives or healthcare proxies in place. Why advance care planning matters in CKD: CKD progresses in many patients despite best management. For older adults, the trajectory toward kidney failure is often combined with progressive frailty, increasing functional dependence, and the development of additional serious illnesses. At some point, the question of whether dialysis serves the patient’s goals — or primarily prolongs a process that is causing suffering without meaningful quality of life — becomes central. Having these conversations before a crisis (a hospitalization, an acute cardiac event, rapidly worsening uremia) allows for thoughtful decision-making with full cognitive capacity and without the pressure of urgency. Components of advance care planning: a healthcare proxy (durable power of attorney for healthcare) designates a person to make medical decisions on the patient’s behalf when they cannot do so themselves — this is the single most important document a CKD patient can have in place. A living will documents specific preferences about life-sustaining treatment (dialysis, mechanical ventilation, resuscitation) under specific circumstances. A POLST (Physician Orders for Life-Sustaining Treatment, also called MOLST in some states) is a physician-signed order form that translates end-of-life preferences into immediately actionable medical orders — particularly useful for patients who may be taken to emergency care in a crisis. Conservative kidney management: for older, frail patients for whom dialysis may not serve their goals, conservative kidney management offers an alternative framework focused on active symptom control, maintenance of function and quality of life, and planning for end-of-life care without dialysis. Conservative management includes: aggressive treatment of all modifiable CKD complications (blood pressure, anemia, acidosis, mineral management, fluid balance) using medications rather than dialysis; proactive palliative care consultation for symptom management (breathlessness, pruritus, pain, fatigue, nausea); and goal-directed social and psychological support. Studies have found that carefully selected older patients treated with conservative management have similar or better quality of life than those who choose dialysis, and some studies report comparable survival in very frail elderly patients. Conservative management is offered at specialist kidney supportive care clinics in many academic centers and is increasingly recognized as a legitimate, evidence-based treatment pathway rather than simply “opting out.” Palliative care in CKD: palliative care is specialized medical care focused on providing relief from the symptoms, pain, and stress of a serious illness — it is appropriate alongside active kidney treatment and does not mean that curative or life-extending treatment is being abandoned. Palliative care consultation in CKD can help with: symptom management for uremic symptoms (pruritus, nausea, breathlessness); pain management with kidney-appropriate medications; advance care planning conversations; support for family caregivers; and — when the time comes — transition to hospice care. Patients can ask for a palliative care referral at any stage of CKD, not only when nearing death. Recognizing when to transition to hospice: hospice care is appropriate for patients who have decided not to pursue dialysis or have chosen to withdraw from dialysis, and whose prognosis is estimated at 6 months or less. Hospice provides expert symptom management for uremic dying — which can include dyspnea, pain, agitation, and altered consciousness — in the setting of the patient’s choice (home, nursing facility, or inpatient hospice). The transition from active kidney management to hospice is not a failure — it is a transition to a different form of expert care focused on comfort and dignity. The NKF patient resource on kidney supportive care and advance care planning is at the NKF advance directive and living will resource. For older adults managing CKD alongside the psychological challenges covered in the mental health article, and monitoring their disease progression over the long term, the article on kidney disease and long-term monitoring provides a framework for tracking all dimensions of CKD over time. The article on kidney disease and mental health covers the psychological dimensions of these care decisions, including how to ensure that decisions reflect values rather than untreated depression.
Nutrition, Hydration, and Weight Management in Older CKD Patients
Nutritional challenges in older adults with CKD are distinct from those in younger patients: while younger CKD patients are primarily concerned with restriction (limiting potassium, phosphorus, sodium, and sometimes protein), older adults with CKD often also face the opposite problem — inadequate dietary intake, protein-energy malnutrition, and unintentional weight loss that accelerates sarcopenia and frailty. Protein-energy malnutrition in older CKD patients: reduced appetite (uremia suppresses appetite through effects on the hypothalamus; concurrent depression adds to this; dental problems common in older adults reduce the ability to eat certain foods; altered taste from uremia and medications reduces food enjoyment) leads to inadequate caloric and protein intake in many elderly CKD patients. This malnutrition — compounded by metabolic acidosis-driven muscle protein catabolism — produces progressive weight loss and muscle wasting that significantly worsens frailty, functional status, and quality of life. Unlike younger CKD patients for whom protein restriction may slow CKD progression, older adults with CKD stage 4–5 are at high risk of protein-energy malnutrition, and the priority is often ensuring adequate protein intake rather than restricting it. Dialysis patients should aim for 1.2–1.5 g/kg/day of dietary protein, and oral nutritional supplements (such as kidney-specific formulas like Nepro or Suplena) can help when appetite and dietary intake are inadequate. Unintentional weight loss as a warning sign: unintentional weight loss of more than 5% of body weight over 6–12 months in a CKD patient is a clinically significant finding that warrants evaluation. Causes may include worsening uremia (requiring dialysis initiation or intensification), uncontrolled diabetes or other metabolic disorders, medication side effects, depression (covered in the article on kidney disease and mental health), occult malignancy, or simply inadequate dietary intake from the combination of restrictions and poor appetite. The care team should be notified about significant weight loss and assess nutritional status formally. Hydration in older CKD patients: older adults have reduced thirst sensation and are at higher risk of both dehydration (which can cause acute kidney injury) and over-hydration (which worsens blood pressure, edema, and pulmonary congestion). CKD patients who still have meaningful residual kidney function should maintain adequate hydration, aiming for pale yellow urine rather than strict fluid restriction — extreme fluid restriction in ambulatory, non-dialysis CKD patients without significant edema or heart failure may worsen kidney perfusion. Conversely, dialysis patients require fluid restriction to limit interdialytic weight gain. The appropriate fluid intake target is highly individualized and should be determined with the care team based on residual kidney function, blood pressure, edema, and dialysis status. Vitamin and mineral supplementation in older CKD patients: older adults with CKD face specific micronutrient risks. Water-soluble vitamins (folate, B vitamins, vitamin C) are removed by dialysis and require supplementation in dialysis patients — standard renal vitamins (such as Nephrocaps) are formulated for this purpose and are preferred over standard multivitamins, which often contain excessive fat-soluble vitamins (A, E, K) that accumulate in kidney disease. Vitamin D supplementation (native vitamin D3) is appropriate in CKD patients with documented deficiency, but supplementation levels should be guided by lab values under nephrology supervision rather than self-prescribed at high doses. The KDIGO guidelines on nutrition in CKD provide specific recommendations for protein and energy intake across CKD stages at the KDIGO nutrition in CKD guidelines page.
Managing kidney disease well in older adulthood is not about maximizing the intensity of treatment — it is about thoughtful alignment of treatment with functional goals, values, and quality of life. The evidence increasingly supports that frail older adults benefit more from optimizing function, managing symptoms, maintaining independence, and preserving meaningful activities than from aggressive interventions that impose significant burdens. A well-coordinated care team that includes a nephrologist experienced with geriatric CKD patients, a renal dietitian, a social worker, and — as needed — palliative care and geriatric specialists, provides the individualized support that older adults with CKD need. The article on slowing kidney disease progression covers the evidence-based interventions that can meaningfully reduce the rate of CKD progression in all age groups, including older adults.
My 82-year-old mother was recently told she needs to consider dialysis for her CKD, and the nephrologist made it sound like there was only one option. I didn’t know conservative management was a legitimate medical pathway until reading this article. The difference in quality of life for someone her age — spending 12+ hours a week on dialysis versus living as she chooses — is enormous. We’re going to request a palliative care consultation before making any decision. Thank you for explaining this so clearly.
Diane, you are asking exactly the right questions. The framing of dialysis as the only option — rather than one option among several — is unfortunately common in nephrology practice, and many patients and families are not offered a full informed consent discussion that includes conservative management. Palliative care teams are skilled at facilitating exactly these goals-of-care conversations and can help clarify your mother’s values and what quality of life means to her. A second nephrology opinion at a center with a dedicated kidney supportive care program is also worth considering for a decision of this magnitude.
I’m 73 with CKD stage 3b and have been worried about frailty for a while — I’ve noticed my grip strength declining and I tire more easily on walks. The section on resistance training being evidence-based for CKD frailty was exactly what I needed to hear to stop avoiding exercise out of fear that it would stress my kidneys. I’ve set up an appointment with a physical therapist who has experience with kidney patients.